

Home > Countermeasures Injury Compensation Program (CICP) > Countermeasures Injury Compensation Program (CICP) Data

# Countermeasures Injury Compensation Program (CICP) Data

# Aggregate Data as of March 1, 2022

The Countermeasures Injury Compensation Program (CICP) provides compensation for covered serious injuries or deaths that, based on compelling, reliable, valid, medical and scientific evidence, are found to be directly caused by the administration or use of a covered countermeasure or are determined to meet the requirements of a countermeasure injury table. Temporal association between administration or use of the covered countermeasure and onset of the injury (i.e., the injury occurs a certain time after the administration or use) is not sufficient, by itself, to prove that an injury is the direct result of a covered countermeasure.

It is important to note that the CICP data only captures the alleged countermeasure(s) and the alleged injuries that CICP requesters list on their Request for Benefits forms (RFB) or claim. The countermeasure or injury listed by the requester on the RFB may or may not be consistent with the requester's medical documentation or the injury resulting in compensation. While requesters are required to identify the alleged countermeasure on their RFB form, they are not required to list the specific manufacturer or trade name on their RFB form.

Furthermore, while requesters must submit their RFB form within 1 year from the administration or use of the covered countermeasure, requesters are permitted to submit the necessary medical records and other documentation, such as a copy of a requester's COVID-19 vaccination record, after the RFB is filed. For the majority of COVID-19 countermeasure claims, including COVID-19 vaccine claims, the CICP is still waiting for records and documentation to be submitted.

#### When was the first CICP claim filed?

The first CICP claim was filed in Fiscal Year (FY) 2010; there are no CICP claims to report on prior to FY 2010.

#### Is the CICP data available by specific manufacturer or trade name?

The CICP does not maintain its aggregated data concerning alleged countermeasures, including vaccines, by specific manufacturer.

#### How many claims has the CICP compensated?

The CICP is the payer of last resort and can only reimburse or pay for medical expenses or lost employment income that are not covered by other third-party payers. To date, the CICP has paid compensation for 30 CICP claims, totaling more than \$6 million. An additional 10 CICP claims were eligible for compensation after a review of the required medical records and documentation; however, in these cases there were no eligible reported medical expenses or lost employment income for the CICP to compensate.

# Has the CICP made any decisions regarding COVID-19 Claims?

As of March 1, 2022, the CICP has not compensated any COVID-19 countermeasures claims. Six COVID-19 countermeasure claims have been denied compensation because the standard of proof for causation was not met and/or a covered injury was not sustained. One COVID-19 countermeasure claim, a COVID-19 vaccine claim due to an anaphylactic reaction, has been determined eligible for compensation and is pending a review of eligible expenses.

# CICP Data for Fiscal Years 2010 – 2022 (As of March 1, 2022)

Total CICP Claims Filed: 7,547

- Claims Eligible for Medical Review: 7,454
  - Eligible for Compensation: 41
    - Compensated: 30
    - No Eligible Reported Expenses: 10
    - Pending: 1

- Pending Review or In Review: 7,049
- Denied: 364
  - Requested Medical Records not Submitted: 135
  - Standard of Proof Not Met and/or Covered Injury not Sustained: 229
- Claims Ineligible for Medical Review: 93
  - Missed Filing Deadline: 38
  - Not CICP Covered Product/Not Specified: 55

#### CICP claims data is provided below in categories pertaining to their status.

- Table 1. Claims filed alleging injuries and deaths from COVID-19 countermeasures
- <u>Table 2. Compensated claims</u>
- <u>Table 3. Eligible for compensation but no reported eligible expenses</u>
- <u>Table 4. Denied because required medical records were not submitted</u>
- Table 5. Denied for failure to meet the standard of proof and/or sustain a covered injury
- Table 6. Ineligible for missing the filing deadline
- Table 7. Ineligible because product is not covered by CICP
- Table 8. Ineligible due to no allegation of administration or use of a covered countermeasure

#### Table 1. Alleged COVID-19 Countermeasure Claims Filed as of March 1, 2022

This table displays the alleged countermeasure and alleged injury/death for each COVID-19 countermeasure claim filed as of March 1, 2022. Of the 7,056 COVID-19 countermeasure claims, 4,097 allege injuries/deaths from COVID-19 vaccines and 2,959 allege injuries/deaths from other COVID-19 countermeasures.

The CICP does not maintain its aggregated data concerning alleged countermeasures, including vaccines, by specific manufacturer or trade name.

Alleged Countermeasure	Alleged Injury/ Death	Number of Claims
Failure to have infection control programs in place, the failure to have adequate infection control in place, the failure to properly train staff, the failure to provide sufficient staff, the failure to cohort infected and uninfected individuals, the failure to provide PPE to staff and residents, the failure to train on the proper use of PPE, the failure to have adequate procedures in place to deal with infection, the failure to adequately monitor residents for signs of infection, the failure to transfer residents to a higher level of care when needed, the failure to adequately treat residents with COVID, the failure to provide appropriate distancing among residents, the failure to properly report the number of COVID-19 cases and deaths to authorities, and others.	Death	295
Anakinra	Death	1
Antiviral	Death	1
Apixaban / Hydroxychloroquine / Methylprednisolone / Zithromax	Death	1
Aspirin / Hydroxychloroquine / Oxygen / Zithromax	Death	1
Auxora	Death	1
Azithromycin	Death	16
Azithromycin / BiPap / Ivermectin / Remdesivir	Death	1
Azithromycin / BiPap / SPO2 / Convalescent Plasma	Acute Respiratory Failure	1
Azithromycin / Cefdinir / G-Tube	Death	1
Azithromycin / Cefdinir / Ibuprofen	Death	1

Ventilator / Lovenox / Plaquenil / Vancomycin / Vitamin D2 / Zozyn	Death	1
Ventilator / Methylprednisolone / Remdesivir	Death	1
Ventilator / Midazolam / Remdesivir / Seasonal Flu Vaccine	Death	1
Ventilator / Permavir / Relenza	Death	1
Ventilator / Plaquenil	Death	1
Ventilator / Remdesivir	Death	45
Ventilator / Remdesivir / Convalescent Plasma	Death	3
Ventilator / Remdesivir / Steroids	Death	1
Ventilator / Remdesivir / Tocilizumab	Death	1
Ventilator / Tocilizumab	Death	1
Ventilator / Tranquilizer	Death	1

#### Table 2. CICP Claims Compensated (Fiscal Years 2010 – 2022) As of March 1, 2022

This table displays the alleged countermeasure, alleged injury, and amount of compensation paid for each compensated CICP claim filed between Fiscal Years 2010 through 2022.

Please note that the number column within the tables are not assigned numbers for a particular claim, but reflect the number of listed items in a given table. Further details concerning the table contents are provided below.

Number	Alleged Countermeasure	Alleged Injury	Compensation Amount
1	H1N1 Vaccine	Guillain-Barrè Syndrome (GBS)	\$2,309.94
2	H1N1 Vaccine	Bursitis	\$385.00
3	H1N1 Vaccine	Anaphylaxis	\$1,885.44
4	Smallpox Vaccine	Myocarditis	\$323,035.75
5	H1N1 Vaccine	Anaphylaxis	\$2,995.23
6	H1N1 Vaccine	Shoulder Pain	\$182.20
7	H1N1 Vaccine	GBS	\$1,762,920.56
8	H1N1 Vaccine	GBS	\$185,479.52
9	H1N1 Vaccine	GBS	\$15,662.07
10	H1N1 Vaccine	GBS	\$106,723.54
11	H1N1 Vaccine	GBS	\$210.75
12	H1N1 Vaccine	GBS	\$2,360.84
13	H1N1 Vaccine	GBS	\$2,364.55
14	H1N1 Vaccine	GBS	\$3,534.00
15	H1N1 Vaccine	GBS	\$6,966.40
16	H1N1 Vaccine	GBS	\$553,945.53

Total			\$6,078,009.22
30	(H1N1 Vaccine)	GBS	\$1,921.75
29	H1N1 Vaccine	GBS	\$220.00
28	H1N1 Vaccine	GBS	\$49,759.00
27	H1N1 Vaccine	GBS	\$571,635.25
26	H1N1 Vaccine	GBS	\$2,316.00
25	H1N1 Vaccine	GBS	\$38.00
24	H1N1 Vaccine	GBS	\$3,500.00
23	H1N1 Vaccine	GBS	\$30.93
22	H1N1 Vaccine	GBS	\$127,435.39
21	H1N1 Vaccine	GBS	\$5,677.77
20	H1N1 Vaccine	GBS	\$27,378.82
19	H1N1 Vaccine	GBS	\$13,581.93
18	H1N1 Vaccine	GBS	\$2,295,929.61
17	H1N1 Vaccine	GBS	\$7,623.45

# Table 3. CICP Claims Eligible for Compensation, but No Eligible Reported Losses or Expenses (Fiscal Years 2010 – 2022) As of March 1, 2022

This table displays the alleged countermeasure and alleged injury for each CICP claim filed between Fiscal Years 2010 through 2022 that was eligible for compensation, but did not have eligible reported losses or expenses.

Please note that the number column within the tables are not assigned numbers for a particular claim, but reflect the number of listed items in a given table. Further details concerning the table contents are provided below.

Number 🗢	Alleged Countermeasure 🗢	Alleged Injury 🗢
1	H1N1 Vaccine	GBS
2	H1N1 Vaccine	GBS
3	Smallpox Vaccine	Myocarditis
4	H1N1 Vaccine	Anaphylaxis
5	H1N1 Vaccine	GBS
6	Smallpox Vaccine	Serum sickness
7	H1N1 Vaccine	Herpes Zoster Outbreak
8	H1N1 Vaccine	GBS
9	H1N1 Vaccine	GBS
10	H1N1 Vaccine	GBS

Table 4. CICP Claims Denied Compensation Because Required Medical Records Were Not Submitted (Fiscal Years 2010 – 2022) As of March 1, 2022